Listen to Jesus Berdeja, MD; Amrita Krishnan, MD, FACP; and Niels van de Donk, MD, PhD, address key questions on CELMoD agent therapy for multiple myeloma, including combination strategies, adverse event management, and where CELMoD agents may best fit within current and future treatment strategies.
In this podcast episode, Jesus Berdeja, MD; Amrita Krishnan, MD, FACP; and Niels van de Donk, MD, PhD, address key questions on CELMoD agent therapy for multiple myeloma, including:
Presenters:
Jesus Berdeja, MD
Director of Multiple Myeloma Research
Greco-Hainsworth Centers for Research
Tennessee Oncology
Nashville, Tennessee
Amrita Krishnan, MD, FACP
Director, Judy and Bernard Center for Myeloma, City of Hope
Nason Hollingsworth Family Chair Myeloma
Executive Director, Hematology, City of Hope Orange County
Professor Hematology/HCT
Irvine, California
Niels van de Donk, MD, PhD
Professor of Hematology
Department of Hematology
Amsterdam UMC, Location VUmc
Amsterdam, Netherlands
Content based on an online CME program supported by an educational grant from Bristol Myers Squibb.
Link to full program:
https://bit.ly/4qvRwQM